Jump to content

TRULANCE® (plecanatide) for Irritable Bowel Syndrome with Constipation in Adults is now Available to Canadians

Recommended Posts

Jeffrey Roberts

LAVAL, QC, Feb. 8, 2022 /CNW Telbec/ - Bausch Health, Canada, part of Bausch Health Companies Inc. (NYSE: BHC) (TSX: BHC), ("Bausch Health" or the "Company") today announced the availability through pharmacies across Canada of its new prescription treatment TRULANCE® (plecanatide).

TRULANCE is approved by Health Canada for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults, and is the first treatment brought to market in Canada by the gastrointestinal division of the Company. Canadian treatment guidelines for IBS-C recommend a variety of non-pharmaceutical and pharmaceutical approaches to treatment, but 70 per cent of surveyed IBS-C patients report no treatment had thus far completely relieved their symptoms.

>> Read full press release

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...